Cure of chronic viral infection by neutralizing antibody treatment

被引:9
作者
Ejrnaes, Mette [1 ]
von Herrath, Matthias G. [1 ]
机构
[1] La Jolla Inst Allergy & Immunol, Dept Dev Immunol, San Diego, CA 92121 USA
关键词
chronic infection; LCMV; autoimmunity; immune-regulation;
D O I
10.1016/j.autrev.2006.09.002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Persistent infections can pose severe health risks. In many cases individuals fail to clear the virus and consequently chronic infection, often associated with severe immunopathology, occurs. For some chronic infections it is known that systemic IL-10 production can be increased. However, it is unclear, whether IL-10 affects the outcome of infection, amount of immunopathology and could be the actual cause for persistence. Conventional interferons (IFN) or anti-viral immunotherapies attempting to augment anti-viral immunity directly in persistent infected individuals have failed to affect the outcome so far, but lowering the viral antigenic load has clear beneficial effects. Therefore, approaching the problem from a different angle is important. The use of neutralizing antibodies is one of the most successful methods to interfere with receptor-ligand interactions in vivo. Optimal designs of therapeutic antibody treatment regimen are important in order to achieve maximal effects with minimal duration of immunosuppression or hyperactivation. In this review we reflect on the effects of a short time administration of a neutralizing cytokine receptor antibody treatment of a chronic infection resulting in the establishment of anti-viral immune responses and viral clearance and speculate on the potential mechanisms involved in this successful therapeutic treatment. (C) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:267 / 271
页数:5
相关论文
共 40 条
[1]
Accapezzato D, 2004, J CLIN INVEST, V113, P963, DOI [10.1172/JCI200420515, 10.1172/JCI200420415]
[2]
AKRIDGE RE, 1994, J IMMUNOL, V153, P5782
[3]
AMEGLIO E, 1994, J BIOL REG HOMEOS AG, V8, P48
[4]
Interleukin-10 therapy - Review of a new approach [J].
Asadullah, K ;
Sterry, W ;
Volk, HD .
PHARMACOLOGICAL REVIEWS, 2003, 55 (02) :241-269
[5]
AUTRAN B, 1995, J IMMUNOL, V154, P1408
[6]
VIRUS-INDUCED IMMUNOSUPPRESSION - IMMUNE SYSTEM-MEDIATED DESTRUCTION OF VIRUS-INFECTED DENDRITIC CELLS RESULTS IN GENERALIZED IMMUNE SUPPRESSION [J].
BORROW, P ;
EVANS, CF ;
OLDSTONE, MBA .
JOURNAL OF VIROLOGY, 1995, 69 (02) :1059-1070
[7]
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs [J].
Bresson, D ;
Togher, L ;
Rodrigo, E ;
Chen, YL ;
Bluestone, JA ;
Herold, KC ;
von Herrath, M .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (05) :1371-1381
[8]
INTERLEUKIN-10 DIFFERENTIALLY REGULATES B7-1 (CD80) AND B7-2 (CD86) EXPRESSION ON HUMAN PERIPHERAL-BLOOD DENDRITIC CELLS [J].
BUELENS, C ;
WILLEMS, F ;
DELVAUX, A ;
PIERARD, G ;
DELVILLE, JP ;
VELU, T ;
GOLDMAN, M .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (09) :2668-2672
[9]
Identification of α-dystroglycan as a receptor for lymphocytic choriomeningitis virus and lassa fever virus [J].
Cao, W ;
Henry, MD ;
Borrow, P ;
Yamada, H ;
Elder, JH ;
Ravkov, EV ;
Nichol, ST ;
Compans, RW ;
Campbell, KP ;
Oldstone, MBA .
SCIENCE, 1998, 282 (5396) :2079-2081
[10]
DING L, 1993, J IMMUNOL, V151, P1224